linjc16/ctgov huggingface dataset:
Testing Spectrosense EVA System for Detection of Breast Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air

Study Overview
=================
Brief Summary
-----------------
Volatile Organic Compounds (VOC) in human breath are captured and analyzed by the Spectrosense EVA system, which is combination of a gas chromatography (GC) and software algorithm. The objective is to obtain a set or sets of VOC bio-markers that will provide the best discrimination between Breast Cancer sick population and healthy population. The gold standard for identifying sick/healthy population is biopsy proven breast cancer.

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Breast Cancer group: Inclusion Criteria: Age from 18 years old Breast cancer positive biopsy Before any treatment Signed Informed Patient Consent Exclusion Criteria: Age under 18 years old Neoadjovant treatment Post surgery for breast cancer A history of any other cancer type, except skin cancer that is not melanoma Healthy group: Inclusion Criteria: Healthy women No history of Breast cancer Signed Informed Patient Consent Exclusion Criteria: History of Breast cancer Breast cancer background in the family A history of any other cancer type, except skin cancer that is not melanoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Breast Cancer<br> | |
| Healthy<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Obtaining a set or sets of VOC bio-markers that will provide the best discrimination between Breast Cancer sick population and healthy population. breast cancer. |  | Upon enrollment. |
Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence

Study Overview
=================
Brief Summary
-----------------
This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and images of HE slices in primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine histopathology image based algorithms that are able to predict molecular pathology or subgroups of gliomas.

Detailed Description
-----------------
Non-invasive and precise prediction for molecular biomarkers such as 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations is challenging. With the development of artificial intelligence, much more potential lies in the histopathology images of HE slices in primary gliomas could be excavated to aid prediction of molecular pathology of gliomas. The creation of a registry for primary glioma with detailed molecular pathology, histopathology image data and with sufficient sample size for deep learning (>1000) provide considerable opportunities for personalized prediction of molecular pathology with non-invasiveness and precision.

Official Title
-----------------
Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Deep Learning or Machine Learning

Conditions
-----------------
Glioma

Intervention / Treatment
-----------------
* Diagnostic Test: Histopathology images based prediction of molecular pathology


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must have radiologically and histologically confirmed diagnosis of primary glioma Life expectancy of greater than 3 months Must receive tumor resection Signed informed consent Exclusion Criteria: No gliomas No sufficient amount of tumor tissues for detection of molecular pathology Patients who are pregnant or breast feeding Patients who are suffered from severe systematic malfunctions

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Histopathology images based prediction of molecular pathology|Histopathology images based prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC of prediction performance | AUC=sensitivity+specificity-1 | up to 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Molecular, Histopathology image, Deep Learning, Machine Learning
Improving Pediatric Safety and Quality With Health Care Information Technology

Study Overview
=================
Brief Summary
-----------------
This study includes four projects aimed to improve the quality and safety of pediatric care through the implementation of four clinical decision support services in the electronic health record (EHR). The four projects will measure the effect of each clinical decision support feature including: weight-based dosing; smart forms for chronic conditions; guideline reminders; and a results manager to track abnormal lab result follow-up. Hypothesis: Implementation of the clinical decision support features will decrease medication errors and adverse drug events, assist physicians in adhering to clinical practice guidelines and protocols for certain chronic illnesses, improve physician follow-up for abnormal lab results, and overall improve the safety and quality of pediatric clinical practice.

Detailed Description
-----------------
please see description above

Official Title
-----------------
Improving Pediatric Safety and Quality With Health Care IT

Conditions
-----------------
Patient Safety, Medication Errors, Medical Records Systems, Computerized, Quality Improvement

Intervention / Treatment
-----------------
* Other: weight based dosing decision support


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Partners-affiliated pediatric practice providers utilizing Longitudinal Medical Record (LMR), which is an electronic health record system. Also the parents of the patients of the above noted pediatric providers. Exclusion Criteria: Non-Partners providers, or Partners providers who do not use LMR. Parents of patients not seen by Partners-affiliated pediatric providers who use LMR.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: dosing decision support<br>weight based dosing decision support | Other: weight based dosing decision support<br>* weight based dosing decision support<br>|
| No Intervention: no decision support<br>no weight based dosing decision support | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact on rates of medication errors | difference in weight related medication prescribing errors by drug class | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Guideline Adherence, Parent Experience of Care, Quality Improvement, Medication Errors, Abnormal Lab Values
Eosinophil and Anticoagulation in COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with Coronavirus disease 2019 (COVID-19). This study aimed to evaluate anti-Factor Xa levels to determine the anticoagulant activity of low molecular weight heparin (LMWH) in COVID-19 patients.

Official Title
-----------------
Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Drug: LMWH


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years, who were diagnosed with COVID-19 and were administered LMWH, agreed to participate in the study were included Exclusion Criteria: Patients with previous coagulopathy, continuous indication of anticoagulant therapy (atrial fibrillation (AF), valve disease), glomerular filtration rate (GFR) <30 mL/min or undergoing dialysis, or with known liver dysfunction were excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID 19 positive patients<br> | Drug: LMWH<br>* COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| subprophylactic anticogulation level | <0.2IU/ml | 14 days |
Association Between Neck Pain and Quality of Sleep

Study Overview
=================
Brief Summary
-----------------
A prospective study to assess the association between the change in quality of sleep and the change in intensity of pain in Spanish patients seen for subacute or chronic neck pain. The objective is to determine the prevalence of sleep alterations, the association between quality of sleep and intensity of pain, degree of disability, intensity of catastrophizing and depression.

Official Title
-----------------
Study of the Association Between Neck Pain and the Quality of Sleep

Conditions
-----------------
Chronic Neck Pain, Disability

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with nonspecific neck pain of more than 14 days duration seen in health centers participating in the study patients who accept to participate and sign the consent form without age limits and regardless of gender Exclusion Criteria: inability to complete the questionnaires (illiteracy, dementia) inflammatory rheumatologic disease, fibromyalgia, cancer in last 5 years
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subacute neck pain; chronic neck pain<br>Patients with subacute or chronic neck pain seen in the Primary Care Centers participating in the study. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of the association between neck pain and quality of sleep in patients with subacute or chronic nonspecific neck pain. |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of the association between quality of sleep and disability, catastrophizing and depression in patients with subacute or chronic nonspecific neck pain. |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
quality of sleep, neck pain, disability, catastrophizing, depression
Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the degree of post-operative ocular inflammation in patients who are undergoing a pars plana vitrectomy.

Conditions
-----------------
Vitrectomy

Intervention / Treatment
-----------------
* Procedure: Pars Plana Vitrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Require pars plana vitrectomy in at least 1 eye Best corrected visual acuity in the study eye between 20/400 and 20/40 Exclusion Criteria: Use of any NSAIDs (topical or systemic) within 14 days Use of topical or systemic steroids within 30 days Active eye infection in either eye Any eye surgery within 6 months Prior pars plana vitrectomy, YAG capsulotomy or uveitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pars Plana Vitrectomy<br>Pars plana vitrectomy performed in study eye on Day 0. | Procedure: Pars Plana Vitrectomy<br>* Pars plana vitrectomy performed in study eye on Day 0.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants With Vitreous Cell Count of 0 | The study eye was dilated and the investigator used an instrument to count the number of visible cells in the vitreous, the jelly-like fluid that fills the back of the eye, using the following scale: 0 (no cells) best, +1 (1-10 cells), +2 (11-30 cells), +3 (31-50 cells) and +4 (>50 cells) worst. | Week 4 |
Intravitreal Ketorolac for Chronic Uveitis: A Investigational Safety Study

Study Overview
=================
Brief Summary
-----------------
Intraocular delivery of ketorolac will be an effective means to treat inflammation and macular edema and prevent structural complications and vision loss in patients with uveitis who are unable to tolerate corticosteroids due to their side effects.

Detailed Description
-----------------
A Phase I safety study of intravitreal ketorolac in patients with chronic inflammation and complications due to inflammation who have either failed medical therapy or who cannot tolerate corticosteroids due to side effects. Specific Aims Test the safety of intraocular injection of 4mg of ketorolac in patients who have intractable uveitis or complications of uveitis such as chronic macular edema who are unable to tolerate corticosteroids due to their side effects. Test the efficacy of intraocular 4m ketorolac of treating inflammation or structural complications of inflammation in patients with uveitis who are unable to tolerate corticosteroids due to their side effects.

Official Title
-----------------
Intravitreal Ketorolac for Chronic Uveitis:A Phase I Investigational Safety Study

Conditions
-----------------
Inflammation

Intervention / Treatment
-----------------
* Drug: Intravitreal Ketorolac


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult volunteers Chronic intractable uveitis or chronic complications of uveitis (macular edema)despite maximal medical treatment Unable to tolerate corticosteroids due to side effects Exclusion Criteria: 18 years or younger Have active ocular infection Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ketorolac<br>4mg intravitreal injection of ketorolac | Drug: Intravitreal Ketorolac<br>* 4mg of intravitreal ketorolac<br>* Other names: ketorolace, tromethamine, preservative free;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety | Baseline and 90 day electroretinogram and goldmann visual fields will be compared to assess for retinal toxicity. | 90 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Inflammation, Macular Edema
Age Dependence of Audiometric Bone Conduction Threshold in Normal Hearing Subjects

Study Overview
=================
Brief Summary
-----------------
Examination of the bone conduction of persons which according to the pure tone audiogram have a normal age related hearing threshold in the air conduction.

Official Title
-----------------
Age Dependence of Audiometric Bone Conduction Threshold in Normal Hearing Subjects

Conditions
-----------------
Air Bone Gap

Intervention / Treatment
-----------------
* Diagnostic Test: audiogram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All pure tone audiograms recorded and available in the system from the beginning of measurement as follows: age related normal hearing threshold level with air conducted pure tone audiogram Exclusion Criteria: age younger than 20 years if inclusion criteria not given

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: audiogram|hearing test|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone conduction Threshold/ Air bone gap in normal hearing subject in relation to age | from the initial establishment of the database until collection of the data | 1960 - 2014 (54 years) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Air bone gap changes in individuals who have received more than one Audiogram |  | 1960 - 2014 (54 years) |
Glycosaminoglycan Scores as Monitoring Biomarkers in Confined Renal Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
In this study, a score based on glycosaminoglycan (GAG) profiling in subjects with suspicion of renal cell carcinoma (RCC) is hypothesized to distinguish malignant masses when early actionable clinical decisions are desirable. For example to diagnose early recurrence after surgical treatment; to screen population at risk of RCC; or to distinguish benign masses from RCC before surgical treatment. To this end, plasma and urine GAGs will be measured in a prospective cohort of patients referred to surgical treatment for RCC. The resulting GAG scores are then correlated to post-surgical recurrence, to post-surgical definitive diagnosis and and to tumor size if RCC. In a subset cohort of patients at high risk of RCC recurrence, plasma and urine GAGs will be monitored to observe its correlation with disease recurrence.

Official Title
-----------------
Specificity and Sensitivity of Glycosaminoglycan Scores in the Early Diagnosis of Recurrent Renal Cell Carcinoma

Conditions
-----------------
Carcinoma, Renal Cell

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients referred for partial or radical nephrectomy for suspicion of renal cell carcinoma Predicted life expectancy over 2 months Standard imaging evaluation 12 weeks prior to inclusion Planned for standard imaging within 16 weeks after start of therapy Exclusion Criteria: Lack of proper compliance to accept continuous samplings.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the receiver operating characteristic (ROC) curve (AUC) for the sensitivity/specificity of plasma/urine glycosaminoglycan scores in the prediction of renal cell carcinoma recurrence after surgery | Radiological assessment of patients with definitive diagnosis of RCC and classified as high risk will be carried out as standard-of-care during follow-up and subjected to correlative analysis relative to the plasma/urine glycosaminoglycan scores (or their change) as assessed by longitudinal sampling. | Every 6 or 12 months after surgery up to 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence-free survival (RFS) | Survival analysis will be performed by Kaplan Meier and significance analysis will use the log-rank test. Cox multivariate analysis will be performed to look at the number and molecular characteristics of the glycosaminoglycan scores as independent prognostic parameters of survival. | Before surgery |